更新于 2月13日

DMPK Research Investigator (MJ017278)

1.6-2.2萬·14薪
  • 北京昌平區(qū)
  • 1-3年
  • 博士
  • 全職
  • 招1人

職位描述

生物藥新藥

General Description:

The DMPK Department of BeiGene is seeking a highly talented and motivated research investigator to join the team. The position requires close collaboration with research teams, developing and executing in vitro and in vivo ADME strategies necessary to provide scientific direction around the characterization of DMPK profile of small molecules.

Responsibilities:

  • Collaborate with discovery colleagues to evaluate compound properties to support medicinal chemistry in drug design and SAR.
  • Independently conducts, analyzes, and interprets in vitro ADME experiments including but not limited to metabolic stability, permeability, protein binding, enzyme induction/inhibition, transporter assays and drug interaction assessments.
  • Independently develops LC-MS/MS methods and works with bio-samples.
  • Independently operates, troubleshoots, and maintains LC-MS/MS equipment.
  • Establish strategy around In Vitro ADME in drug research, while exploring new technology and methods.

Requirements:

  • Doctorate (Ph.D.) with at least 2 years of experience in the pharmaceutical or biotechnology industries.
  • A significant level of hands-on experience in the conduct of studies
  • A keen eye for detail and the ability to focus on clear study outcomes
  • Strong interpersonal, communication, problem solving and collaborative qualities to deliver high quality results in a fast-paced environment.


百濟(jì)神州全球勝任力
當(dāng)我們通過以下十二項(xiàng)全球勝任力,展現(xiàn)出 "患者為先"、"無界協(xié)作"、"銳意創(chuàng)新 "和 "追求卓越 "的價(jià)值觀時(shí),我們就能幫助全世界更多患者獲得更多負(fù)擔(dān)得起的藥品。
●團(tuán)隊(duì)協(xié)作
●提供并征求坦誠及可行的反饋
●自我認(rèn)知
●兼容并蓄
●積極主動(dòng)
●開拓精神
●持續(xù)學(xué)習(xí)
●擁抱變化
●結(jié)果導(dǎo)向
●分析性思維/數(shù)據(jù)分析
●卓越財(cái)務(wù)
●清晰溝通
BeiGene Global Competencies
When we exhibit our values of Patients First, Collaborative Spirit, Bold Ingenuity and Driving Excellence, through our twelve global competencies below, we help get more affordable medicines to more patients around the world.
●Fosters Teamwork
●Provides and Solicits Honest and Actionable Feedback
●Self-Awareness
●Acts Inclusively
●Demonstrates Initiative
●Entrepreneurial Mindset
●Continuous Learning
●Embraces Change
●Results-Oriented
●Analytical Thinking/Data Analysis
●Financial Excellence
●Communicates with Clarity
求職者隱私申明:
百濟(jì)神州致力于尊重和保護(hù)您的個(gè)人信息權(quán)利,并承諾依據(jù)合法、正當(dāng)、必要和誠信的原則處理您的個(gè)人信息(包括個(gè)人敏感信息 )。
由于百濟(jì)神州在全球范圍內(nèi)開展業(yè)務(wù),我們可能需要基于人力資源管理等合理業(yè)務(wù)目的而將您的個(gè)人信息發(fā)送和/或存儲(chǔ)在位于您所在國家以外其他國家(例如:美國)的服務(wù)器和數(shù)據(jù)庫中,詳情參見百濟(jì)神州《求職者隱私政策》(百濟(jì)神州官網(wǎng) - 隱私政策 - 求職者隱私政策)。
如您主動(dòng)向我們提供您的簡歷信息或其他個(gè)人信息,則視為您已經(jīng)充分理解并確認(rèn)接受百濟(jì)神州《求職者隱私政策》內(nèi)容。如您對此有任何疑問的,請勿提交簡歷信息或其他個(gè)人信息。
BeiGene is committed to respect and protect your personal information rights, and will process your personal information, including your sensitive personal information, based on the principles of legality, legitimacy, necessity, and integrity.
Due to the reasonable business need for human resource management as a result of BeiGene’s global operation, your personal information may be transferred and/ or stored in a server/database located in a third country (e.g., the United States) other than your own country. For further details, please refer to BeiGene Job Applicant Privacy Policy (BeiGene official website - Privacy Policy - Job Applicant Privacy Policy).
If you voluntarily provide your resume or other personal information to us, it is deemed as you have thoroughly acknowledged and accepted BeiGene Job Applicant Privacy Policy. If you have any concern, please DO NOT submit your resume or any other personal information.

工作地點(diǎn)

北京市昌平區(qū)科學(xué)園路30號(hào)

職位發(fā)布者

張婧媛/人事經(jīng)理

立即溝通
公司Logo百濟(jì)神州北京
About BeiGene BeiGene is a publically traded(BGNE, NASDAQ), globally focused biopharmaceutical company dedicated to becoming a leader in the discovery and development of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer. Our cancer biology platform addresses the importance of tumor-immune system interactions and the value of primary tumor biopsies in developing new cancer models. We have a global team of over 200 individuals, including over 150 scientists and clinicians, and a world-renowned scientific advisory board, with deep scientific talent, extensive pharmaceutical experience, and a commitment to improving the lives of cancer patients around the world. Our clinical pipeline is comprised of novel oral small molecules and monoclonal antibodies(mAb) for cancer, including an anti-PD-1 monoclonal antibody, a best-in-class BTK inhibitor, a RAF dimer inhibitor, a best-in-class PARP inhibitor, and a variety of combination clinical studies. In addition, our robust preclinical programs are expected to generate more small molecule and mAb drugs for clinical development in coming years. For more information, please visit our website at www.beigene.com.
公司主頁